recombinant platelet-activating factor acetylhydrolase

Recombinant platelet-activating factor acetylhydrolase (rPAF-AH) is a biologic enzyme therapy designed to supplement or replace endogenous platelet-activating factor acetylhydrolase activity. This enzyme rapidly degrades the proinflammatory mediator platelet activating factor (PAF) and oxidized phospholipids into inactive metabolites by hydrolyzing the sn‑2 ester bond of these molecules. By inactivating these mediators—which are implicated in systemic inflammatory states such as severe sepsis and acute respiratory distress syndrome—rPAF-AH was developed to reduce inflammation and organ dysfunction. Clinical trials have shown that rPAF-AH is well tolerated but did not significantly reduce mortality in severe sepsis or affect outcomes in asthma at studied doses[1][5][6][8]. The drug has also been investigated for its potential antiatherogenic properties due to its ability to bind lipoproteins and protect them from oxidation[7].

Brand names

Pafase

Other names

recombinant human platelet-activating factor acetylhydrolasePAF-acetylhydrolase (human, recombinant)1-alkyl-2-acetylglycerophosphocholine esterase2-acetyl-1-alkylglycerophosphocholine esteraseGroup-VIIA phospholipase A2gVIIA-PLA2gVIIA-PLA-2gVIIA-PLA 2LDL-associated phospholipase A2LDL-PLA(2)lipoprotein-associated phospholipase A2PAF 2-acylhydrolasePAF2-acylhydrolasePAF-2-acylhydrolasePAF acetylhydrolasephospholipase A2 group VII (platelet-activating factor acetylhydrolase plasma)Platelet-activating factor acetylhydrolase